Comparison 3. SENSITIVITY ANALYSIS: RISPERIDONE vs PLACEBO (based on attrition).

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Mental state: 1. no clinically significant response (defined by PANSS/BPRS) ‐ short term (up to 12 weeks)	6		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
1.1 defined by PANSS/BPRS <20% decline	6	864	Risk Ratio (M‐H, Random, 95% CI)	0.64 [0.52, 0.78]
1.2 defined by PANSS/BPRS <20% decline (without studies with >50% left the study early)	3	589	Risk Ratio (M‐H, Random, 95% CI)	0.77 [0.67, 0.88]